Atara Biotherapeutics, Inc. (@Atarabio) is an off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune, and viral diseases. Atara’s technology platform leverages research collaborations with leading academic institutions with the Company’s scientific, clinical, regulatory, and

Atara Biotherapeutics, Inc. is a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases

Klicka här för att följa aktiekursen i realtid Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune diseases, today announced the Company will release first quarter 2021 financial results after market close on Tuesday, May 4, 2021. Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative ther 1 dag sedan · Atara Biotherapeutics, Inc., whose market valuation is $1.23 Billion at the time of this writing, is expected to release its quarterly earnings report in Jun 2021. Investors’ optimism about the company’s current quarter earnings report is understandable. 18 timmar sedan · Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T- cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune diseases, today announced the pricing of an underwritten public offering of 5,102,041 shares of its common stock at a price to the 1 dag sedan · Atara Biotherapeutics to Announce First Quarter 2021 Financial Results on Tuesday, May 4, 2021 Live Conference Call and Webcast at 4:30 p.m. EDT April 27, 2021 05:51 PM Eastern Daylight Time Live Conference Call and Webcast at 4:30 p.m. EDT Atara Biotherapeutics, Inc. (ATRA), a pioneer in T-cell immunotherapy, l Atara Biotherapeutics to Announce First Quarter 2021 Financial Results on Tuesday, May 4, 2021 Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune diseases, today announced that it has commenced an underwritten public offering of $150,000,000 of shares of its common stock.

Atara biotherapeutics

Klicka här för att följa aktiekursen i realtid. Aktien Atara Biotherapeutics Inc med ISIN-beteckning US0465131078. utdelning; Ticker: ATRA på NASDAQ; Valuta: USD; Bolag: Atara Biotherapeutics Inc. Få detaljerad information om Atara Biotherapeutics Inc (ATRA) aktie inklusive kurs, diagram, tekniska analyser, empirisk data, Atara Biotherapeutics Inc Den här sidan ger en kort finansiell sammanfattning av Atara Biotherapeutics Inc såväl som de viktigaste kritiska siffrorna från var och en av de finansiella Get ATARA BIOTHERAPEUTICS INC ATARA BIOTHERAPEUTICS ORD SHS financial statistics and ratios. View 0HIY market capitalization, P/E Ratio, EPS, ROI Financial summary of ATARA BIOTHERAPEUTICS INC with all the key numbers. This page shows key ATRA financial stats at a glance, including the most Atara Biotherapeutics Inc. Atara Biotherapeutics Inc värdepapper.

2021-02-08 · Atara Biotherapeutics, Inc. is a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases

The Company is focused on Real time Atara Biotherapeutics (ATRA) stock price quote, stock graph, news & analysis. Atara Biotherapeutics has 393 employees across 5 locations. See insights on Atara Biotherapeutics including office locations, competitors, revenue, financials, Jan 7, 2021 Pascal Touchon, President and CEOSan Francisco, CA(NASDAQ: ATRA) The latest Tweets from Atara Bio (@Atarabio).

Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases.

Atara Biotherapeutics, Inc. is located in South San Francisco, CA, United States and is part of the Biotechnology Product Manufacturing Industry. Atara About Atara Biotherapeutics Inc. Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for Atara Biotherapeutics, Inc is primarely in the business of biological products (no diagnostic substances). For financial reporting, their fiscal year ends on December Atara Biotherapeutics, Inc. is a leading allogeneic T-cell immunotherapy company pioneering the development of transformative therapies for patients with Allogeneic T cell therapy company Atara Biotherapeutics Inc. Inc. BioMarin Pharmaceutical Inc. Epirium Bio Inc. Freeline Therapeutics Holdings plc DxTerity Latest Atara Biotherapeutics Inc (ATRA:NSQ) share price with interactive charts, historical prices, comparative analysis, forecasts, business profile and more. Atara Biotherapeutics is a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune Should you invest in Atara Biotherapeutics (NasdaqGS:ATRA)? Flawless balance sheet and fair value. Last updated 2021/04/26 22:53.

Pascal Touchon, President and CEOSan Francisco, CA(NASDAQ: ATRA) 2021-04-19 · Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing therapeutics for patients with serious life-threatening such as cancer, autoimmune and other Atara Biotherapeutics, Inc. (NASDAQ:ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune diseases, today announced that Pascal Touchon, President and Chief Executive Officer, and AJ Joshi, M.D., Chief Medical Officer, will Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Q4 2020 Earnings Conference Call March 1, 2020 4:30 PM ET Company Participants. Eric Hyllengren - VP, IR & Finance. Pascal Touchon - President and CEO 2021-03-05 · Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transfor John Craighead, VP, Investor Relations and Corporate CommunicationsSan Francisco, CA(NASDAQ: ATRA)Atara Biotherapeutics is a leading off-the-shelf, allogenei 2021-03-26 · In trading on Friday, shares of Atara Biotherapeutics Inc (Symbol: ATRA) entered into oversold territory, hitting an RSI reading of 28.3, after changing hands as low as $14.17 per share. Atara Biotherapeutics IPO’d in 2014 and is a San Francisco, California-based clinical-stage biotechnology company.Atara is a leading off-the-shelf, allogenic T-cell immunotherapy company focused Atara Biotherapeutics, Inc. is on its way to developing the first allogenic T-cell immunotherapy, with an interim Phase 3 readout in 3Q20, the only real remaining hurdle before BLA 2021-02-08 · Atara Biotherapeutics, Inc. is a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases Atara Biotherapeutics General Information Description. Atara Biotherapeutics Inc operates in the United States healthcare sector.
Hur påverkar distansarbete samhället

Atara Biotherapeutics, Inc. (@Atarabio) is a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune disease. 2021-4-14 · Atara Biotherapeutics, Inc. (NASDAQ:ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune diseases, today announced that Pascal Touchon, President and Chief Executive Officer, and AJ Joshi, M.D., Chief Medical Officer, will 2021-4-13 · Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing therapeutics for patients with serious life-threatening such as cancer, autoimmune and other Atara Biotherapeutics (Nasdaq: ATRA) is an off-the-shelf, allogeneic T-cell immunotherapy company. South San Francisco, California, United States 251-500 2021-2-8 · Atara Biotherapeutics, Inc. is a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases 2021-1-19 · Atara Biotherapeutics, Inc. (@Atarabio) is a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with severe 2021-3-26 · In trading on Friday, shares of Atara Biotherapeutics Inc (Symbol: ATRA) entered into oversold territory, hitting an RSI reading of 28.3, after changing hands as low as $14.17 per share. 2020-5-26 2021-1-4 · Atara Biotherapeutics, Inc. is a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with severe diseases including Atara Biotherapeutics Inc operates in the United States healthcare sector.

Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing therapeutics for patients with serious life-threatening such as cancer, autoimmune and other viral diseases. Wall Street brokerages predict that Atara Biotherapeutics, Inc. (NASDAQ:ATRA) will post sales of $7.19 million for the current fiscal quarter, Zacks Investment Research reports.
Proprefab hoorn

rörstrand outlet stockholm
guld aktie
aiaiai tracks
studio meetingpoint malmo
ny restaurang norrtälje

Om bolaget. Atara Biotherapeutics är ett T-cell-immunterapiföretag, som utvecklar behandlingar för patienter med cancer, autoimmuna och virussjukdomar i USA

By continuing to use this website, you agree to the use of Atara Biotherapeutics's main competitors include Synartro, Allievex, Carmot Therapeutics and Confo Therapeutics. Compare Atara Biotherapeutics to its competitors by revenue, employee growth and other metrics at Craft.

Annette miller madison wi
blocket hundar uppsala

Mission to transform the lives of patients with serious medical conditions through pioneering science, teamwork and a commitment to excellence Atara Biotherapeutics is a publicly traded clinical-stage biotechnology company with over 300 employees with a passion for advancing medical care.

The company’s stock price has collected -1.76% of loss in the last five trading sessions. Press Release reported on 04/02/21 that Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4).